{
    "nctId": "NCT02743598",
    "officialTitle": "Effects of Liraglutide on Cognition, Chronic Inflammation and Glycemic Control in Overweight and Obese, HIV-infected Subjects With Type 2 Diabetes.",
    "inclusionCriteria": "* HIV controlled on therapy for at least 12 weeks\n* Viral load \\< 200 copies\n* BMI \\>27 to 45\n* Diagnosis of DM type 2 with A1-C \\>7 to 15\n* Participants must be willing to comply with all study related procedures\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* Personal or family history of pancreatitis\n* Medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)\n* Gastroparesis\n* Allergy to liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue\n* Weight loss drugs other than metformin\n* Type 1 diabetes mellitus or diabetic ketoacidosis\n* Known major cognitive deficit dementia, history of head trauma with loss of consciousness \\>30 min, history of stroke, current central nervous system (CNS) disorder such as seizures or opportunistic CNS infection\n* Renal insufficiency defined as creatinine clearance \\< 60 mL/min\n* Active opportunistic infections\n* Pregnancy or breastfeeding\n* Unstable cardiovascular disease with hospitalization within 1 year for acute coronary syndrome\n* Decompensated heart failure\n* Substance abuse\n* Active alcohol or opioid substitution therapy\n* Serious or unstable medical or psychological conditions that would compromise the subject's safety for successful participation"
}